Phase 1 Abemaciclib (CDK4/CDK6 inhibitor) and 5-fluorouracil study in refractory colorectal cancer

This Phase 1 trial by the National Cancer Institute evaluates the safety, tolerability, and optimal dosing of abemaciclib combined with 5-fluorouracil in patients with metastatic, refractory colorectal cancer. Patients receive oral abemaciclib twice daily for 28-day cycles with intravenous 5-fluorouracil on days 1 and 15, alongside imaging and biospecimen collection. The study explores a novel combination potentially offering a therapeutic option for a challenging patient group.